Topical Insulin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-01

Study Completion Date

2020-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Purpose: To evaluate the clinical outcome of patients with refractory Neurotrophic Keratopathy (NK) in stages 2 and 3 treated with topical insulin.

Methods: A retrospective, observational analysis of eyes with NK in stages 2 and 3 refractory to standard medical and/or surgical treatment which were treated with topical insulin. Topical insulin (1 unit per mL) was applied 4 times a day; treatment was continued until persistent epithelial defect (PED) or ulcer resolved and then tapered accordingly. The primary outcome of the study was the complete resolution of the PED or ulcer. Best-corrected visual acuity (BCVA), days until complete resolution as well as anterior segment photographs were obtained.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy

NCT05940376

Corneal Ulcer Neurotrophic Corneal Ulcer Diabetes Mellitus

UNKNOWN

Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus

NCT06601101

Keratoconus Cornea Disease Eye Diseases +1 more

RECRUITING PHASE3

Topical Insulin Drops for the Treatment of Neurotrophic Keratopathy.

NCT05321251

Neurotrophic Keratitis

WITHDRAWN PHASE2/PHASE3

Topical Autologous Insulin Application for the Treatment of Corneal Epithelium Defect After Ocular Surgeries

NCT01031888

Corneal Epithelial Defects After Ocular Surgeries

COMPLETED PHASE1

Topical Insulin Versus Autologous Serum After Corneal Surgeries

NCT05331859

Corneal Epithelial Wound

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study type

Retrospective, observational, single-center study at the Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia e Espinho, EPE.

Data was obtained from patients' medical records and anterior segment photographs from October 1, 2018 to November 1, 2020.

Each participant and/or relative was given a detailed explanation and a written informed consent regarding possible alternatives, risks and benefits of off-label use of topical insulin drops. This study was approved by the board of Centro Hospitalar de Vila Nova de Gaia e Espinho (UIEC-2020-981914339595fa024c567ec5). This study complied with the tenets of the Declaration of Helsinki.

Patient selection

Patients included in this study were provided from the Cornea department of the Ophthalmology center in Centro Hospitalar de Vila Nova de Gaia e Espinho. Every patient included had an established diagnosis of NK (ICD10: H16.2) in stages 2 or 3 that was refractory to standard medical and/or surgical treatment and underwent treatment with topical insulin. All patients underwent complete ophthalmological exam including best-corrected visual acuity, slit-lamp examination, corneal sensitivity in the center and four quadrants of the cornea and fundoscopic evaluation. NK was graded based on slit-lamp and fluorescein stain findings - stage 2: epithelial defect (with or without a rim of loose epithelium) without stromal ulceration; stage 3: corneal ulceration and/or stromal lysis.

Topical insulin preparation and administration

Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2ºC) and were applied four times a day. A therapeutic corneal CL was placed in every patient and fluoroquinolone drops were applied to prevent possible CL side-effects.

Treatment was continued until NK PED or Ulcer resolved and tapered accordingly. Patients would discontinue topical insulin if the condition did not improve within 30 days or worsen. Follow-up was ensured on the 3rd,5th, and 7th day and then individualized during the full-extent of treatment. Anterior segment photos were taken on each visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Corneal Ulcer Corneal Perforation Corneal Epithelium Defect Neurotrophic Keratitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patients were administered eyedrops enriched with insulin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Eyes with established diagnosis of NK in stages 2 or 3 refractory to standard treatment\* that underwent topical insulin treatment.

The diagnosis of NK was based on the following criteria:

1. Decreased or absence of corneal sensation; AND
2. Corneal injury \[PED and/or corneal ulcer\] refractory to standard treatment\*; AND
3. Clinical history of conditions related to trigeminal innervation impairment;

* Standard treatment - lubrication with artificial tears, topical and/or oral antibiotics, topical and/or oral steroids, antiviral drugs, punctal plugs, therapeutic CL, amniotic membrane surgery and temporary tarsorrhaphy.´

We excluded every patient with corneal ulcer and signs of infection.

Eligible Sex

ALL

Accepts Healthy Volunteers

No